Advertisement
UK markets close in 2 hours 58 minutes
  • FTSE 100

    8,022.59
    -1.28 (-0.02%)
     
  • FTSE 250

    19,679.14
    +79.75 (+0.41%)
     
  • AIM

    753.14
    +3.96 (+0.53%)
     
  • GBP/EUR

    1.1612
    +0.0023 (+0.20%)
     
  • GBP/USD

    1.2399
    +0.0049 (+0.39%)
     
  • Bitcoin GBP

    53,280.38
    +94.31 (+0.18%)
     
  • CMC Crypto 200

    1,420.37
    +5.61 (+0.40%)
     
  • S&P 500

    5,010.60
    +43.37 (+0.87%)
     
  • DOW

    38,239.98
    +253.58 (+0.67%)
     
  • CRUDE OIL

    81.14
    -0.76 (-0.93%)
     
  • GOLD FUTURES

    2,321.00
    -25.40 (-1.08%)
     
  • NIKKEI 225

    37,552.16
    +113.55 (+0.30%)
     
  • HANG SENG

    16,828.93
    +317.24 (+1.92%)
     
  • DAX

    18,012.80
    +152.00 (+0.85%)
     
  • CAC 40

    8,064.70
    +24.34 (+0.30%)
     

Rosacea Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape

ReportLinker
ReportLinker

Summary This reports provides a data-driven overview of the current and future competitive landscape in Rosacea therapeutics. Synopsis

New York, July 15, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Rosacea Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape" - https://www.reportlinker.com/p06292923/?utm_source=GNW
- In 2022, there will be more than 47 million diagnosed prevalent cases of rosacea across 16 pharmaceutical markets.
- There are 10 FDA approved branded marketed drugs for the treatment of rosacea.
- The rosacea pipeline consists of over 32 pharmaceuticals spanning all stages of development, with approximately 50% of drugs in early-stage development.
- Commercial sponsors dominate clinical trial development in rosacea, with the US emerging as the key countries for conducting trials in rosacea.
- Deals involving acquisition of rosacea assets were the most common type of deals globally.
- Only three players are developing products for the treatment of rosacea in the late-stage suggesting very limited change in the market scenario in immediate future.

Scope
Rosacea: Competitive Landscape in 2022 combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include -
- Disease Landscape
- Disease Overview
- Epidemiology Overview
- Treatment Overview
- Marketed Products Assessment
- Breakdown by Mechanism of Action, Molecule Type and Route of Administration
- Pipeline Assessment
- Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
- Late-to-mid-stage Pipeline Drugs
- Phase Transition Success Rate and Likelihood of Approval
- Clinical Trials Assessment
- Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
- Enrolment Analytics, Site Analytics, Feasibility Analysis
- Deals Landscape
- Mergers, Acquisitions, and Strategic Alliances by Region
- Overview of Recent Deals
- Commercial Assessment
- Key Market Players
- Future Market Catalysts

Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the Rosacea market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Rosacea market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Read the full report: https://www.reportlinker.com/p06292923/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001